An estimated 34 million Americans have diabetes, and approximately 90-95% of these individuals have type 2 diabetes (T2D). Diabetes is associated with premature mortality and imposes higher costs of care, estimated in 2017 at $327 billion. Real-time continuous glucose monitoring (RT-CGM) can help improve glycemic management in the T2D population and can be associated with a reduction in medical-related costs. This presentation will address why A1C is a population health metric that is insufficient for optimal diabetes care as well as highlight the digital health partnership capabilities of RT-CGM which demonstrates favorable health outcomes in the T2D population. Join the webinar and learn how the Dexcom G6 can help your patients improve their health and glycemic outcomes.
After completing this webinar, Participants will have a better understanding of:
1.) why the A1C metric is not the ideal quality measure for populations with diabetes
2.) the use and features of real-time continuous glucose monitoring (RT-CGM) for people with diabetes
3.) the digital health partnership capabilities with RT-CGM